Pediatric Inhaled Insulin: Afrezza Faces FDA Decision on May 29, 2026

Pediatric inhaled insulin (Afrezza) is up for FDA review in children and adolescents aged 4 through 17 with type 1 or type 2 diabetes. The pivotal INHALE-1 trial missed its prespecified HbA1c noninferiority margin in the primary analysis but met it in a modified one — and the answer matters for needle-averse families.

April 25, 2026 · 4 min read

Why Pediatric Inhaled Insulin Is in the News Right Now

Pediatric inhaled insulin returns to the regulatory spotlight ahead of a May 29, 2026 FDA decision on Afrezza for children and adolescents aged 4 through 17 with type 1 or type 2 diabetes. The agency accepted MannKind’s supplemental Biologics License Application (sBLA) in October 2025 and assigned the Prescription Drug User Fee Act (PDUFA) target action date roughly five weeks from now.

If approved, Afrezza would become the first needle-free mealtime insulin available to children — a meaningful prospect for needle-averse families navigating multiple daily injections (MDI) or pump therapy. The complete INHALE-1 results, published in Diabetes Care in January 2026, complicate the picture: the trial missed its prespecified primary endpoint in the intent-to-treat (ITT) analysis but met it in a modified ITT after excluding one nonadherent participant.

The Background

Afrezza is a rapid-acting human insulin powder delivered through a small inhaler at the start of meals. The FDA approved it for adults in 2014 on the strength of phase 3 trials in type 1 and type 2 diabetes.

Important limitations of use have always shadowed the drug. It is contraindicated in chronic lung disease such as asthma or chronic obstructive pulmonary disease, not recommended in current or recent smokers, and not indicated for diabetic ketoacidosis. Pulmonary function testing — including FEV1 (forced expiratory volume in 1 second) — is required at baseline, after six months, and annually thereafter.

The 2026 American Diabetes Association Standards of Care now ask clinicians to evaluate inhaled insulin as a prandial option at every patient visit. The pediatric inhaled insulin question — whether children as young as four can safely use a daily mealtime inhaler — has been open for a decade.

The Evidence So Far: INHALE-1

INHALE-1 (NCT04974528) is the pivotal evidence base for the pediatric submission. The 26-week, multicenter, open-label, randomized phase 3 trial enrolled 230 children aged 4–17 with type 1 (98%) or type 2 (2%) diabetes, all on basal-bolus MDI at baseline. Mean age was 12.6 years; 38% were female. Participants were randomized 1:1 to Afrezza plus once-daily basal insulin or to a rapid-acting analog (insulin aspart, lispro, or glulisine) plus basal insulin. The primary endpoint was change in HbA1c at 26 weeks against a noninferiority margin of 0.4%.

Headline findings:

Primary ITT analysis: Between-group difference 0.435% — exceeded the noninferiority margin
Modified ITT (excluding 1 nonadherent participant): Difference 0.370% — within the margin
CGM time in range: Comparable between arms
Lung function: No clinically significant change; mean FEV1 stayed at roughly 96–100% of predicted in both arms
Hypoglycemia (level 2/3): No significant difference between groups
Treatment satisfaction: Higher in the Afrezza arm
Weight gain: Less in the Afrezza arm

The 26-week extension study, published by Beck et al in Diabetes Technology & Therapeutics in February 2026, reported slight HbA1c deterioration over time but no new safety signals. INHALE-1 began Afrezza dosing at roughly a 2:1 conversion from rapid-acting analog units.

Where Experts Disagree

The most contested element is the missed ITT primary endpoint. ITT preserves randomization and is the conservative regulatory standard; modified ITT analyses are accepted in some contexts but invite scrutiny when they hinge on a single excluded patient.

“Inhaled insulin performed as well as injected rapid acting insulin on average.” — Michael Haller, MD, MS-CI, professor and chief of pediatric endocrinology, University of Florida; INHALE-1 protocol chair

Independent commentators have flagged three additional caveats. First, the trial was open-label, raising questions about whether higher satisfaction reflects pharmacology or novelty. Second, the comparator was MDI, not automated insulin delivery (AID) systems — hybrid closed-loop pumps that increasingly define the standard of care for pediatric type 1 diabetes and consistently outperform MDI on time in range. Third, the 2:1 dose conversion raises real-world questions about cost, drug supply, and titration. Haller and several coauthors disclosed financial relationships with MannKind, the trial sponsor; the trial was MannKind-funded.

Pediatric Inhaled Insulin: The Practical Question

For pediatric endocrinologists, the question is less “does pediatric inhaled insulin work?” than “for which patient?” The plausible niche is the older child or adolescent for whom needle aversion is a barrier to adherence and for whom an AID system is unavailable, declined, or unaffordable. The 4-to-7 age group raises additional questions about reliable inhaler technique and the feasibility of pulmonary function testing.

Children with asthma — common at this age — face a contraindication and would not be candidates regardless of approval. For families, the appeal of a needle-free mealtime option is obvious, but shared decision-making will need to address the pulmonary function testing requirements, the smoking and lung disease contraindications, and the absence of head-to-head data versus pumps.

What to Watch For

Pediatric inhaled insulin will face one of three outcomes by May 29, 2026: approval, a complete response letter, or a formal review extension.
Whether the agency accepts the modified ITT analysis as supportive given the missed ITT noninferiority — and how labeling addresses real-world effectiveness expectations.
Updated pediatric labeling for pulmonary function monitoring frequency and contraindications in childhood asthma.
Comparative signals from the ongoing INHALE-1ST single-arm trial in newly diagnosed type 1 diabetes (ages 10 to <18, NCT07224321) and any future head-to-head data versus AID systems.
Payer coverage decisions and supply logistics if approval is granted, particularly the cost implications of the roughly 2:1 dose conversion from rapid-acting analogs.

Sources

MannKind Corporation. MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes. Press release, October 2025. MannKind Press Release on FDA Acceptance of Pediatric Afrezza sBLA
Haller MJ, Kanapka L, Monzavi R, et al; INHALE-1 Study Group. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care, January 2026;49(1):179–187. Diabetes Care — INHALE-1 Phase 3 Pediatric Results (Haller et al, 2026)
Beck RW, Kanapka L, Monzavi R, et al; INHALE-1 Study Group. Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study. Diabetes Technology & Therapeutics, February 2026. Diabetes Technology & Therapeutics — INHALE-1 Extension Phase
ClinicalTrials.gov. NCT04974528: Afrezza INHALE-1 Study in Pediatrics. ClinicalTrials.gov Record for INHALE-1
American Diabetes Association. Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes. ADA Newsroom, June 22, 2025. ADA Press Release on INHALE-1 Results
Managed Healthcare Executive. With a PDUFA Date on the Horizon, Another Trial of Afrezza Begins. March 4, 2026. Managed Healthcare Executive — Afrezza Pediatric PDUFA Coverage
HCPLive. FDA Accepts Inhaled Insulin (Afrezza) sBLA for Pediatric Diabetes. 2026. HCPLive — FDA Acceptance of Pediatric Afrezza sBLA